Page 12 - CUA KIDNEY CANCER HANDBOOK 2020

Completed Trials of Adjuvant Targeted Therapy
Trial N Patient Treatment Treatment Primary
characteristics arms duration endpoint
S-TRAC : 615 High-risk patients Sunitinib 1 year Disease-free
1
Sunitinib trial in Placebo survival
adjuvant renal (positive results)
cancer treatment
2
ASSURE : 1,943 Non-metastatic Sunitinib 1 year Disease-free
Adjuvant sorafenib RCC; disease stage Sorafenib (9 treatment survival
or sunitinib for II-IV; high-risk Placebo cycles) (negative results)
unfavourable RCC
SORCE : 1,711 Patients with high- Sorafenib 3 years Disease-free
3
Sorafenib in and intermediate- Sorafenib/Placebo survival
patients with risk resected RCC Placebo (negative results)
resected primary
RCC at high/
intermediate risk
of relapse
EVEREST : 1,545 Pathological stage Everolimus 9 treatment cycles Recurrence-free
4
Everolimus for intermediate or very Placebo survival
renal cancer high-risk patients (results pending)
ensuing surgical with full or partial
therapy nephrectomy
PROTECT : 1,538 Patients with Pazopanib 1 year Disease-free
5
Pazopanib as an moderately high or Placebo survival
adjuvant treatment high risk of relapse (negative results)
for localized RCC with nephrectomy
of localized or
locally advanced
RCC
ATLAS : Adjuvant 724 High-risk, Axitinib 3 years Disease-free
6
axitinib therapy of non-metastatic RCC Placebo survival
renal cell cancer in with nephrectomy (negative results)
high risk patients

1 Ravaud A, et al. N Engl J Med. 2016;375:2246-54.
2 Haas NB, et al. Lancet. 2016;387:2008-2016.
3 Eisen TQG, et al. Presented at: ESMO Congress 2019; September 27-October 3, 2019: Barcelona, Spain. Abstract LBA56.
4 Clinicaltrials.gov. NCT01120249. Accessed: June 4, 2020.
Motzer RJ, et al. J Clin Oncol. 2017;35:3916-3923.
5
6 Gross-Goupil M, et al. Ann Oncol. 2018;29 :2371-2378.

8 Practical Approaches to Managing Advanced Kidney Cancer